USA. Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatmen…

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review.  Adams KK, Waters K, Sobieraj DM.  Addict Sci Clin Pract. 2025 Feb 20;20(1):19. doi: 10.1186/s13722-025-00548-z. PMID: 3…

Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder Montgomery C, Abbasi Y, De Silva D, Gittins R, Jones A, Van Hout MC. …

Navigating Buprenorphine Therapy: A Closer Look at Microdosing vs. Macrodosing for Pain Management and Opioid Addiction - A Narrative Review.  Merhavy ZI, Flores M, Rivera E, Gizzarelli J, Ruxmohan S, Quinonez J.  Addict Health. 2024 Oct…

Emergency Clinician Buprenorphine Initiation, Subsequent Prescriptions, and Continuous Prescriptions.  Dekker AM, Schriger DL, Herring AA, Samuels EA.  JAMA. Published online February 19, 2025. doi:10.1001/jama.2024.2…

Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance.  Tsakiridou G, Angelerou MF, Efentakis P, Margaritis A, Papanastasiou AM, Kalantzi L.  Pharmaceutics. 2024 Dec 26;17(1):21…